These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 35757417)

  • 1. Follicular-Phase GnRH Agonist Protocol Is Another Choice for Polycystic Ovary Syndrome Patients With Lower LH/FSH and Lower AMH Levels Without Increasing Severe OHSS Risk.
    Gao R; Liao X; Huang W; Zeng R; Qin L; Bai P
    Front Endocrinol (Lausanne); 2022; 13():905263. PubMed ID: 35757417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose Nomogram of Individualization of the Initial Follicle-Stimulating Hormone Dosage for Patients with Polycystic Ovary Syndrome Undergoing IVF/ICSI with the GnRH-Ant Protocol: A Retrospective Cohort Study.
    Si M; Qi X; Zhen X; Yang C; Tian T; Long X; Qiao J
    Adv Ther; 2023 Sep; 40(9):3971-3985. PubMed ID: 37395872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LH on GnRH-ant day to basal LH affects the IVF/ICSI outcome of PCOS women undergoing GnRH-antagonist protocol.
    Wei Y; Luan T; Shen J; Zhang J; Zhang J; Su Y; Ling X; Li X; Zhao C
    Int J Gynaecol Obstet; 2024 Feb; 164(2):624-632. PubMed ID: 37724009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type.
    Lambalk CB; Banga FR; Huirne JA; Toftager M; Pinborg A; Homburg R; van der Veen F; van Wely M
    Hum Reprod Update; 2017 Sep; 23(5):560-579. PubMed ID: 28903472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of Letrozole (LE) in controlled ovarian stimulation (COS) in patients at high risk to develop ovarian hyper stimulation syndrome (OHSS). A prospective randomized controlled pilot study.
    Tshzmachyan R; Hambartsoumian E
    J Gynecol Obstet Hum Reprod; 2020 Feb; 49(2):101643. PubMed ID: 31563697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conventional GnRH antagonist protocols versus long GnRH agonist protocol in IVF/ICSI cycles of polycystic ovary syndrome women: a systematic review and meta-analysis.
    Kadoura S; Alhalabi M; Nattouf AH
    Sci Rep; 2022 Mar; 12(1):4456. PubMed ID: 35292717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flexible GnRH Antagonist Protocol versus Progestin-primed Ovarian Stimulation (PPOS) Protocol in Patients with Polycystic Ovary Syndrome: Comparison of Clinical Outcomes and Ovarian Response.
    Xiao ZN; Peng JL; Yang J; Xu WM
    Curr Med Sci; 2019 Jun; 39(3):431-436. PubMed ID: 31209815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controlled Ovarian Stimulation Using Medroxyprogesterone Acetate and hMG in Patients With Polycystic Ovary Syndrome Treated for IVF: A Double-Blind Randomized Crossover Clinical Trial.
    Wang Y; Chen Q; Wang N; Chen H; Lyu Q; Kuang Y
    Medicine (Baltimore); 2016 Mar; 95(9):e2939. PubMed ID: 26945402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Supplementation with human menopausal gonadotropin in the gonadotropin-releasing hormone antagonist cycles of women with high AMH: Pregnancy outcomes and serial hormone levels.
    Chen LH; Chin TH; Huang SY; Yu HT; Chang CL; Huang HY; Wang HS; Soong YK; Wu HM
    Taiwan J Obstet Gynecol; 2021 Jul; 60(4):739-744. PubMed ID: 34247817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can AMH levels predict the need to step up FSH dose for controlled ovarian stimulation following a long GnRH agonist protocol in PCOS women?
    Huang H; Gao H; Shi Y; Deng B; He X; Lin J; Li P
    Reprod Biol Endocrinol; 2023 Dec; 21(1):121. PubMed ID: 38110998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is oocyte maturation rate associated with triptorelin dose used for triggering final oocyte maturation in patients at high risk for severe ovarian hyperstimulation syndrome?
    Lainas GT; Lainas TG; Sfontouris IA; Chatzimeletiou K; Venetis CA; Bosdou JK; Tarlatzis BC; Grimbizis GF; Kolibianakis EM
    Hum Reprod; 2019 Sep; 34(9):1770-1777. PubMed ID: 31384921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Müllerian hormone dynamics during GNRH-antagonist short protocol for IVF/ICSI in women with varying ovarian reserve levels.
    Melado Vidales L; Fernández-Nistal A; Martínez Fernández V; Verdú Merino V; Bruna Catalán I; Bajo Arenas JM
    Minerva Ginecol; 2017 Apr; 69(2):128-134. PubMed ID: 27310675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of progestin-primed ovarian stimulation in women with polycystic ovary syndrome undergoing
    Yang L; Liang F; Yuan Y; Luo X; Wang Q; Yao L; Zhang X
    Front Endocrinol (Lausanne); 2023; 14():1224858. PubMed ID: 37795363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of gonadotropin-releasing hormone agonists and antagonists in assisted reproduction cycles of polycystic ovarian syndrome patients.
    Hosseini MA; Aleyasin A; Saeedi H; Mahdavi A
    J Obstet Gynaecol Res; 2010 Jun; 36(3):605-10. PubMed ID: 20598044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Increased risk of early pregnancy loss and lower live birth rate with GNRH antagonist vs. long GNRH agonist protocol in PCOS women undergoing controlled ovarian hyperstimulation].
    Kdous M; Chaker A; Bouyahia M; Zhioua F; Zhioua A
    Tunis Med; 2009 Dec; 87(12):834-42. PubMed ID: 20209851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel GnRH antagonist protocol based on LH levels versus traditional flexible GnRH antagonist protocol in PCOS patients undergoing in vitro fertilization: study protocol for a randomized controlled, non-inferiority trial.
    Liu S; Lv YS; Han S; Liu M; Ma S; Ren H; Li Y
    Trials; 2022 Aug; 23(1):654. PubMed ID: 35964041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis and prediction of risk factors of ovarian hyperstimulation caused by Long-acting GnRH agonist protocol in follicular phase.
    Ni YH; Zhang HL; Jiang WW
    Eur Rev Med Pharmacol Sci; 2022 May; 26(9):3261-3268. PubMed ID: 35587077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT).
    Lainas TG; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas GT; Alexopoulou E; Kolibianakis EM
    Hum Reprod; 2010 Mar; 25(3):683-9. PubMed ID: 20008886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.